Tech Company Financing Transactions
Adnexus Therapeutics Funding Round
Adnexus Therapeutics closed a $27 million Series B financing round on 6/26/2006. Backers included Venrock, Atlas Venture and Flagship Pioneering.
Transaction Overview
Company Name
Announced On
6/26/2006
Transaction Type
Venture Equity
Amount
$27,000,000
Round
Series B
Investors
Proceeds Purpose
Adnexus Therapeutics intends to use the proceeds from the financing to fund development of its lead product candidate, Angiocept through Phase II clinical development.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
100 Beaver St.
Waltham, MA 02453
USA
Waltham, MA 02453
USA
Phone
Website
Email Address
Overview
Adnexus is a private biotechnology company developing a breakthrough class of protein therapeutics known as AdNectins.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
President
John Edwards
Vice President
Cliff Bechtold
Vice President
Ray Camphausen
Vice President
Sharon Cload
VP - Product Management
Kelledy Manson
VP - R & D
Eric Furfine
Browse more venture capital transactions:
Prev: 6/26/2006: Scintera Networks venture capital transaction
Next: 6/27/2006: SANRAD venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site come from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs